Risk of Share Dilution From the Exercise of Stock Acquisition Rights
First written in FY2021. 16 of 19 entries say "Materialised", first in FY2022-Q3. Latest entry: 2026-07-22.
The whole theme swung hardest in 2017: 37 of 68 companies on the "Worse" side.
- 2026-07-22MaterialisedShare Issuance and Disposal
「(2) Type and number of shares to be issued 13,000 common shares of the company」
Although this resulted from performance-linked, transfer-restricted stock-based compensation rather than exercise of share acquisition rights, the issuance of 13,000 new shares was completed, meaning potential dilution was realized through an actual share issuance. The original thread remains unchanged. - FY2026MaterialisedAnnual report
「1 April 2025–31 March 2026 68,250 8,435,050 12,726 565,059 12,724 539,916」
The exercise of stock acquisition rights in the fiscal year ending March 2026 resulted in the issuance of 68,250 shares, and the potential for dilution of equity value materialized in the form of actual share issuance. - FY2026-H1MaterialisedAnnual report
「The increase resulted from the exercise of share acquisition rights.」
A total of 2,250 shares were added through the exercise of stock acquisition rights from April to September 2024, and the potential for dilution of equity value materialized in the form of actual share issuance. - FY2025MaterialisedAnnual report
「Increase from the issuance of new shares through the exercise of stock acquisition rights 60,750 shares」
The exercise of stock acquisition rights in the fiscal year ending March 2025 resulted in the issuance of 60,750 shares, and the potential for dilution materialized in the form of actual share issuance through increases in shares outstanding, share capital and capital surplus. - FY2025-H1MaterialisedAnnual report
「1 April 2024–30 September 2024 30,750 8,321,800 2,720 539,660 2,690 514,526」
The exercise of stock acquisition rights from April to September 2023 resulted in the issuance of 30,750 shares, and the potential for dilution of equity value materialized in the form of actual share issuance through increases in shares outstanding, share capital and capital surplus. - FY2024MaterialisedAnnual report
「1 April 2023–31 March 2024 54,000 8,279,050 5,541 530,076 5,495 504,984」
The exercise of stock acquisition rights in the fiscal year ending March 2024 resulted in the issuance of 54,000 shares, and the potential for dilution materialized in the form of actual share issuance through increases in shares outstanding, share capital and capital surplus. - FY2024-Q3MaterialisedAnnual report
「1 October 2023–31 December 2023 3,000 8,231,800 258 525,191 255 500,139」
The exercise of stock acquisition rights during the third quarter resulted in the issuance of 3,000 shares, and the potential for dilution materialized in the form of actual share issuance through increases in shares outstanding, share capital and capital surplus. - FY2024-Q2MaterialisedAnnual report
「1 July 2023–30 September 2023 3,750 8,228,800 398 524,933 395 499,884」
The exercise of stock acquisition rights during the second quarter resulted in the issuance of 3,750 shares, increasing the total number of shares outstanding, share capital and capital surplus. A further increase of 3,000 shares in October 2023 is also reported, with the potential for dilution materializing in the form of actual share issuance. - FY2023MaterialisedAnnual report
「Stock options outstanding during the consolidated fiscal year, with 15,750, 4,500 and 750 exercised」
A total of 21,000 shares were issued through the exercise of stock acquisition rights from April 2022 to March 2023. The potential for dilution of equity value has materialized in the form of actual share issuance. - FY2023-Q3MaterialisedAnnual report
「The increase resulted from the exercise of share acquisition rights.」
During the third quarter, 4,500 shares were added through the exercise of stock acquisition rights, and the potential for dilution materialized in the form of actual share issuance through increases in shares outstanding, share capital and capital surplus. - FY2023-Q2MaterialisedAnnual report
「1 July 2022–30 September 2022 3,000 8,207,050 333 522,544 331 497,512」
During the second quarter, 3,000 shares were added through the exercise of stock acquisition rights, and the potential for dilution materialized in the form of increases in shares outstanding, share capital and capital surplus. - FY2022MaterialisedAnnual report
「1 April 2021–31 March 2022 42,750 8,204,050 5,709 522,211 5,686 497,181」
A total of 42,750 shares were added through the exercise of stock acquisition rights from April 2021 to March 2022, increasing the total number of shares outstanding, share capital and capital surplus. The potential for dilution of equity value has materialized in the form of actual share issuance. - FY2022-Q3MaterialisedAnnual report
「The increase resulted from the exercise of share acquisition rights.」
A total of 15,750 shares were added through the exercise of stock acquisition rights from October to December 2021. The possibility of dilution of equity value associated with the exercise of stock acquisition rights has materialized in the form of actual share issuance. - FY2022-Q2Update on stock acquisition rights exercisesAnnual report
「The increase resulted from the exercise of share acquisition rights.」
A total of 6,000 shares were added through the exercise of stock acquisition rights from July to September 2021. The increase in the number of shares and the potential for dilution associated with the exercise of stock acquisition rights continue to be disclosed. - FY2022-Q1Update on stock acquisition rights exercisesAnnual report
「The increase resulted from the exercise of share acquisition rights.」
It is stated that 2,250 shares were added through the exercise of stock acquisition rights from April to June 2021, followed by a further 5,250 shares in July 2021. - FY2021First statedAnnual report
「If these stock acquisition rights are exercised, the value of our shares on a per-share basis may be diluted.」
The possibility of dilution of per-share equity value resulting from the exercise of stock acquisition rights granted to officers and employees is described.